{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:43Z","timestamp":1740126823475,"version":"3.37.3"},"reference-count":218,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Eine akute oder chronische Nierensch\u00e4digung bei gleichzeitig bestehender Lebererkrankung stellt ein h\u00e4ufiges Problem dar und geht im weiteren klinischen Verlauf mit zahlreichen Komplikationen sowie einer gesteigerten Dialysepflichtigkeit und Mortalit\u00e4t einher.<\/jats:p><jats:p>Die Pr\u00e4valenz einer chronischen Niereninsuffizienz (CNI) bei Patienten mit Lebererkrankungen ist hoch, nicht zuletzt wegen parallel bestehender Komorbidit\u00e4ten (z.\u200aB. metabolisches Syndrom, chronische Entz\u00fcndungsprozesse, Hyperkoagulabilit\u00e4t, Hyperfibrinolyse, Diabetes mellitus, Dyslipid\u00e4mie usw.). Doch nicht jede chronische Verschlechterung der Nierenretentionsparameter l\u00e4sst sich auf ein hepatorenales Syndrom zur\u00fcckf\u00fchren. Neben diesem sind die h\u00e4ufigsten Ursachen der CNI bei bestehenden Lebererkrankungen die diabetische Nephropathie, die alkoholassoziierte IgA-Nephropathie, die mit Hepatitis C assoziierte membranoproliferative Glomerulonephritis und die mit Hepatitis B assoziierte membran\u00f6se Glomerulonephritis.<\/jats:p><jats:p>Koexistente Erkrankungen, \u00e4hnlich bzw. parallel ablaufende pathophysiologische Mechanismen und \u00fcberlappende Erscheinungsbilder stellen hinsichtlich der Ursachenfindung und entsprechenden Behandlung der CNI im Rahmen einer existenten Lebererkrankung eine Herausforderung an den Kliniker dar. Diese \u00dcbersichtsarbeit skizziert sowohl h\u00e4ufige als auch seltene Entit\u00e4ten, die zu einer chronischen Nierensch\u00e4digung in diesem speziellen Patientenkollektiv f\u00fchren, und zeigt einen \u00dcberblick zu therapeutischen M\u00f6glichkeiten.<\/jats:p>","DOI":"10.1055\/a-1402-1502","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:12:36Z","timestamp":1615939956000},"page":"560-579","source":"Crossref","is-referenced-by-count":4,"title":["Ursachen der chronischen Nierensch\u00e4digung in Patienten mit Lebererkrankungen \u2013 Pathophysiologie und Therapiem\u00f6glichkeiten"],"prefix":"10.1055","volume":"59","author":[{"given":"Florian Gunnar","family":"Scurt","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Nieren- und Hochdruckerkrankungen, Diabetologie und Endokrinologie, Medizinische Fakult\u00e4t der Otto-von-Guericke-Universit\u00e4t, Magdeburg, Deutschland"},{"name":"Health Campus Immunology, Infectiology and Inflammation, Otto von Guericke University, Magdeburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Bose","sequence":"additional","affiliation":[{"name":"Health Campus Immunology, Infectiology and Inflammation, Otto von Guericke University, Magdeburg, Germany"},{"name":"Universit\u00e4tsklinik f\u00fcr Gastroenterologie, Hepatologie und Infektiologie, Medizinische Fakult\u00e4t der Otto-von-Guericke-Universit\u00e4t, Magdeburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Canbay","sequence":"additional","affiliation":[{"name":"Ruhr-Universit\u00e4t Bochum, Medizinische Klinik, Universit\u00e4tsklinikum Knappschaftskrankenhaus Bochum GmbH, Bochum, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R","family":"Mertens","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Nieren- und Hochdruckerkrankungen, Diabetologie und Endokrinologie, Medizinische Fakult\u00e4t der Otto-von-Guericke-Universit\u00e4t, Magdeburg, Deutschland"},{"name":"Health Campus Immunology, Infectiology and Inflammation, Otto von Guericke University, Magdeburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-2346","authenticated-orcid":false,"given":"Christos","family":"Chatzikyrkou","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Nieren- und Hochdruckerkrankungen, Diabetologie und Endokrinologie, Medizinische Fakult\u00e4t der Otto-von-Guericke-Universit\u00e4t, Magdeburg, Deutschland"},{"name":"Health Campus Immunology, Infectiology and Inflammation, Otto von Guericke University, Magdeburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"ref1","first-page":"349","volume-title":"Renal Dysfunction in Chronic Liver Disease","author":"A Slack","year":"2010"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"G Targher","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrgastro.2012.79","article-title":"Increased risk of cardiovascular disease and chronic kidney disease in NAFLD","volume":"9","author":"E Bonora","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/MCG.0000000000001325","article-title":"Evaluation of Renal Disease in Patients With Cirrhosis","volume":"54","author":"E L Lum","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2169\/internalmedicine.50.5043","article-title":"The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease","volume":"50","author":"Y Arase","year":"2011","journal-title":"Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2337\/dc13-2704","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes","volume":"37","author":"G Targher","year":"2014","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/lt.25454","article-title":"Impact of Chronic Kidney Disease on Outcomes in Cirrhosis","volume":"25","author":"F Wong","year":"2019","journal-title":"Liver Transpl"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41581-019-0218-4","article-title":"Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis","volume":"16","author":"J CQ Velez","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112458","article-title":"Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence","volume":"9","author":"G Mazzolini","year":"2020","journal-title":"Cells"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00108-018-0550-y","article-title":"[New aspects of nonalcoholic steatohepatitis]","volume":"60","author":"N Stefan","year":"2019","journal-title":"Internist (Berl)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"L A Adams","year":"2017","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2337\/dc06-1539","article-title":"Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease","volume":"30","author":"K G Tolman","year":"2007","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1464-5491.2010.03093.x","article-title":"High prevalence of diabetes mellitus in patients with liver cirrhosis","volume":"27","author":"N Wlazlo","year":"2010","journal-title":"Diabet Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jhep.2015.08.011","article-title":"Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease","volume":"63","author":"V Grancini","year":"2015","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.2215\/CJN.05050610","article-title":"Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis","volume":"5","author":"G Targher","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/gut.51.6.870","article-title":"Mechanisms of hyperinsulinaemia in Child's disease grade B liver cirrhosis investigated in free living conditions","volume":"51","author":"A V Greco","year":"2002","journal-title":"Gut"},{"issue":"S 02","key":"ref17","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.2337\/dc08-s264","article-title":"Insulin resistance and hyperinsulinemia: is\u00a0hyperinsulinemia the cart or the horse?","volume":"31","author":"M H Shanik","year":"2008","journal-title":"Diabetes Care"},{"key":"ref18","first-page":"1444","article-title":"[Studies on histopathology of pancreas in portal hypertension]","volume":"81","author":"M Saitoh","year":"1984","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.diabet.2012.11.002","article-title":"Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside","volume":"39","author":"K Gariani","year":"2013","journal-title":"Diabetes Metab"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2337\/diacare.2951096","article-title":"Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study","volume":"29","author":"A Lecube","year":"2006","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1128\/JVI.00050-12","article-title":"Hepatitis C virus activates the mTOR\/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance","volume":"86","author":"S K Bose","year":"2012","journal-title":"J Virol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"D J Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1665-2681(19)31905-2","article-title":"Dipeptidyl peptidase IV (DDP IV) in NASH patients","volume":"6","author":"Y H Balaban","year":"2007","journal-title":"Ann Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3748\/wjg.v19.i15.2298","article-title":"Dipeptidyl peptidase-4: a key player in chronic liver disease","volume":"19","author":"M Itou","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clinbiochem.2005.07.016","article-title":"Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis","volume":"39","author":"E Yagmur","year":"2006","journal-title":"Clin Biochem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/s0168-8278(01)00232-x","article-title":"Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis \u2013 amelioration by liver transplantation","volume":"36","author":"K Sebekova","year":"2002","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11892-013-0453-1","article-title":"Advanced glycation end products (AGE) and diabetes: cause, effect, or both?","volume":"14","author":"H Vlassara","year":"2014","journal-title":"Curr Diab Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/hep.21611","article-title":"Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A","volume":"46","author":"V Christen","year":"2007","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/liv.13337","article-title":"Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?","volume":"37","author":"E Orsi","year":"2017","journal-title":"Liver Int"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF01788899","article-title":"The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study","volume":"30","author":"J Rahier","year":"1987","journal-title":"Diabetologia"},{"key":"ref31","first-page":"244","article-title":"Diabetic nephropathy: a global and growing threat","volume":"16","author":"S C Tang","year":"2010","journal-title":"Hong Kong Med J"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/jcm4050998","article-title":"Renal Biopsy in Type 2 Diabetic Patients","volume":"4","author":"E Espinel","year":"2015","journal-title":"J Clin Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2337\/dc15-0184","article-title":"Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes","volume":"38","author":"A S Krolewski","year":"2015","journal-title":"Diabetes Care"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2169\/internalmedicine.38.918","article-title":"Significance of oral glucose tolerance test for the diagnosis of diabetes mellitus in patients with liver cirrhosis","volume":"38","author":"E Imano","year":"1999","journal-title":"Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3748\/wjg.v10.i15.2284","article-title":"Determination of glycated hemoglobin in patients with advanced liver disease","volume":"10","author":"T Lahousen","year":"2004","journal-title":"World J Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1572-0241.2005.00307.x","article-title":"Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis","volume":"101","author":"T Nishida","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1210\/js.2017-00183","article-title":"Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test","volume":"1","author":"T Nishida","year":"2017","journal-title":"J Endocr Soc"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"154001","DOI":"10.1016\/j.metabol.2019.154001","article-title":"Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!","volume":"101","author":"G Ranjbar","year":"2019","journal-title":"Metabolism"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040121","article-title":"Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?","volume":"11","author":"M Tacelli","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11892-019-1244-0","article-title":"Personalized Management of Type 2 Diabetes","volume":"19","author":"P R Peter","year":"2019","journal-title":"Curr\u00a0Diab Rep"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"568632","DOI":"10.3389\/fphys.2020.568632","article-title":"Repurposing Antidiabetic Drugs for Cardiovascular Disease","volume":"11","author":"M Schubert","year":"2020","journal-title":"Front Physiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21061907","article-title":"Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis","volume":"21","author":"Y Sumida","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.phrs.2019.01.042","article-title":"Management of diabetes mellitus in patients undergoing liver transplantation","volume":"141","author":"V Grancini","year":"2019","journal-title":"Pharmacol Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"552","DOI":"10.4103\/ijem.IJEM_79_18","article-title":"Hepatogenous Diabetes: An Underestimated Problem of Liver Cirrhosis","volume":"22","author":"R Kumar","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"H JL Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMc1917241","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply","volume":"382","author":"J JV McMurray","year":"2020","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"M Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"V Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"S D Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of Canagliflozin in Patients with Baseline eGFR <30 ml\/min per 1.73 m(2): Subgroup Analysis of the Randomized CREDENCE Trial","volume":"15","author":"G Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"C Estes","year":"2018","journal-title":"J Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e1001680","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"G Musso","year":"2014","journal-title":"PLoS Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"59","author":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O","year":"2016","journal-title":"Diabetologia"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups","volume":"47","author":"Non-alcoholic Fatty Liver Disease Study G, Lonardo A, Bellentani S et al","year":"2015","journal-title":"Dig Liver Dis"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Z Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/ncpneph0954","article-title":"Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease","volume":"4","author":"J Kendrick","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrneph.2009.173","article-title":"Emerging risk factors and markers of chronic kidney disease progression","volume":"5","author":"F Kronenberg","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1055\/s-0029-1222606","article-title":"Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome","volume":"35","author":"G Targher","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1055\/s-0033-1334866","article-title":"Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic\/thrombotic and vascular complications","volume":"39","author":"G Targher","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"C D Byrne","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","article-title":"Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease","volume":"21","author":"G Musso","year":"2015","journal-title":"Trends Mol Med"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e48801","DOI":"10.1371\/journal.pone.0048801","article-title":"Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver","volume":"7","author":"M A Lanaspa","year":"2012","journal-title":"PLoS One"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","article-title":"Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver","volume":"287","author":"M A Lanaspa","year":"2012","journal-title":"J Biol Chem"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1074\/jbc.RA118.006158","article-title":"Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats","volume":"294","author":"L G Sanchez-Lozada","year":"2019","journal-title":"J\u00a0Biol Chem"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease","volume":"150","author":"Q M Anstee","year":"2016","journal-title":"Gastroenterology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"M Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"e0132640","DOI":"10.1371\/journal.pone.0132640","article-title":"Influence of the PNPLA3 rs738409 Polymorphism on Non-Alcoholic Fatty Liver Disease and Renal Function among Normal Weight Subjects","volume":"10","author":"K Oniki","year":"2015","journal-title":"PLoS One"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/hep.27643","article-title":"PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease","volume":"62","author":"G Musso","year":"2015","journal-title":"Hepatology"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.diabet.2019.01.011","article-title":"Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease","volume":"45","author":"A Mantovani","year":"2019","journal-title":"Diabetes Metab"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/liv.14251","article-title":"PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels","volume":"40","author":"D Q Sun","year":"2020","journal-title":"Liver Int"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/hep.30625","article-title":"Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD","volume":"70","author":"G Targher","year":"2019","journal-title":"Hepatology"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e12539","DOI":"10.1111\/ijpo.12539","article-title":"Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity","volume":"14","author":"P Marzuillo","year":"2019","journal-title":"Pediatr Obes"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12967","article-title":"Efficacy and safety of drugs for nonalcoholic steatohepatitis","author":"B Shen","year":"2021","journal-title":"J Dig Dis"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/apt.13860","article-title":"Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis","volume":"45","author":"E Vilar-Gomez","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.kint.2018.02.030","article-title":"Secondary IgA nephropathy","volume":"94","author":"M K Saha","year":"2018","journal-title":"Kidney Int"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00108-019-0588-5","article-title":"[Immunoglobulin A nephropathy]","volume":"60","author":"C Seikrit","year":"2019","journal-title":"Internist (Berl)"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/00313029500169053","article-title":"Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation","volume":"27","author":"R A Axelsen","year":"1995","journal-title":"Pathology"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"735","DOI":"10.7326\/0003-4819-144-10-200605160-00007","article-title":"Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation","volume":"144","author":"B M McGuire","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jhep.2012.04.028","article-title":"Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: effects on long-term renal function after liver transplantation","volume":"57","author":"Y Calmus","year":"2012","journal-title":"J Hepatol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1097\/TXD.0000000000000708","article-title":"Renal Outcomes in Patients With IgA Nephropathy Undergoing Liver Transplant: A Retrospective Cohort Study","volume":"3","author":"M S Hommos","year":"2017","journal-title":"Transplant Direct"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"H Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/ki.2011.276","article-title":"Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases","volume":"80","author":"E Tissandie","year":"2011","journal-title":"Kidney Int"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1055\/a-1088-1582","article-title":"[Paradigm shift in understanding Acute kidney injury in patients with chronic liver disease: From pathophysiology to defining disease entities]","volume":"58","author":"F G Scurt","year":"2020","journal-title":"Z Gastroenterol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2215\/CJN.12451018","article-title":"Hepatorenal Syndrome","volume":"14","author":"C Francoz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00467-018-4051-y","article-title":"IgA nephropathy secondary to liver disease","volume":"33","author":"J Singhal","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/0016-5085(92)91519-a","article-title":"Immunoglobulin A and interleukin 6 form a positive secretory feedback loop: a study of normal subjects and alcoholic cirrhotics","volume":"103","author":"J Deviere","year":"1992","journal-title":"Gastroenterology"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semnephrol.2007.10.004","article-title":"Secondary IgA nephropathy","volume":"28","author":"S Pouria","year":"2008","journal-title":"Semin Nephrol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"T Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial","volume":"74","author":"L J Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrneph.2013.59","article-title":"Treatment of IgA nephropathy and Henoch-Schonlein nephritis","volume":"9","author":"J Floege","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"G Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A Randomized, Controlled Trial\u00a0of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction","volume":"28","author":"R A Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"C Pozzi","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2215\/CJN.02300215","article-title":"Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy","volume":"11","author":"C Sarcina","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"318","author":"J Lv","year":"2017","journal-title":"JAMA"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/ndt\/gfw285","article-title":"Pro: STOP immunosuppression in IgA nephropathy?","volume":"31","author":"C Pozzi","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study","volume":"26","author":"V Tesar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.asn.0000103869.08096.4f","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"C Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"C Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria","volume":"26","author":"H K Smerud","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"B C Fellstrom","year":"2017","journal-title":"Lancet"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"e21000","DOI":"10.1097\/MD.0000000000021000","article-title":"Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison","volume":"99","author":"G Ismail","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31407","article-title":"Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting AASLD Guidelines","author":"J M Vierling","year":"2020","journal-title":"Hepatology"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/liv.14062","article-title":"Autoimmune hepatitis: Current and future therapeutic options","volume":"39","author":"I Doycheva","year":"2019","journal-title":"Liver Int"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010189","article-title":"A New Vision of IgA Nephropathy: The Missing Link","volume":"21","author":"F Sallustio","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000077065","article-title":"Hepatitis B virus-associated nephropathy","volume":"24","author":"R Bhimma","year":"2004","journal-title":"Am J Nephrol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.2215\/CJN.09180816","article-title":"Viral-Associated GN: Hepatitis B and Other Viral Infections","volume":"12","author":"W L Kupin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/ki.2013.249","article-title":"Treatment of hepatitis B in patients with chronic kidney disease","volume":"84","author":"C L Pipili","year":"2013","journal-title":"Kidney Int"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ki.1990.32","article-title":"Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations","volume":"37","author":"R J Johnson","year":"1990","journal-title":"Kidney Int"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","article-title":"Membranous nephropathy related to hepatitis B virus in adults","volume":"324","author":"K N Lai","year":"1991","journal-title":"N Engl J Med"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"456","DOI":"10.5414\/cn107615","article-title":"Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy","volume":"78","author":"P Li","year":"2012","journal-title":"Clin Nephrol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2215\/CJN.04321007","article-title":"Idiopathic membranous nephropathy: diagnosis and treatment","volume":"3","author":"F C Fervenza","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s004670050417","article-title":"In situ hybridization of hepatitis B DNA in hepatitis B-associated glomerulonephritis","volume":"12","author":"X Y He","year":"1998","journal-title":"Pediatr Nephrol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000431331","article-title":"Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy","volume":"41","author":"Q Xie","year":"2015","journal-title":"Am J Nephrol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ki.1995.27","article-title":"Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon","volume":"47","author":"C Y Lin","year":"1995","journal-title":"Kidney Int"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"e0160437","DOI":"10.1371\/journal.pone.0160437","article-title":"A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy","volume":"11","author":"Y Yang","year":"2016","journal-title":"PLoS One"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/tropej\/fmx058","article-title":"Successful Use of Entecavir in Hepatitis B-associated Membranous Nephropathy","volume":"64","author":"V Mahajan","year":"2018","journal-title":"J Trop Pediatr"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"e9756","DOI":"10.1097\/MD.0000000000009756","article-title":"Effect of tenofovir on renal function in patients with chronic hepatitis B","volume":"97","author":"W J Jung","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","author":"E De Clercq","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ekir.2017.09.009","article-title":"Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy","volume":"3","author":"L Berchtold","year":"2018","journal-title":"Kidney Int Rep"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/23744235.2019.1693624","article-title":"Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy","volume":"52","author":"A R Buonomo","year":"2020","journal-title":"Infect Dis (Lond)"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/infdis\/jiaa256","article-title":"High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy","volume":"222","author":"W Y Chang","year":"2020","journal-title":"J Infect Dis"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00005792-199007000-00002","article-title":"Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course","volume":"69","author":"V S Venkataseshan","year":"1990","journal-title":"Medicine (Baltimore)"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jceh.2013.06.001","article-title":"Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis","volume":"3","author":"A Sharma","year":"2013","journal-title":"J Clin Exp Hepatol"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.aohep.2019.06.022","article-title":"Mechanisms of kidney dysfunction in the cirrhotic patient: Non-hepatorenal acute-on-chronic kidney damage considerations","volume":"19","author":"M J Mucino-Bermejo","year":"2020","journal-title":"Ann Hepatol"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11926-002-0027-8","article-title":"Polyarteritis nodosa and microscopic polyangiitis: etiologic and diagnostic considerations","volume":"4","author":"L B Hughes","year":"2002","journal-title":"Curr Rheumatol Rep"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/art.27240","article-title":"Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database","volume":"62","author":"C Pagnoux","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","article-title":"Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients","volume":"84","author":"L Guillevin","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/art.20401","article-title":"Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa","volume":"51","author":"L Guillevin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaut.2015.08.003","article-title":"Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group","volume":"65","author":"G de Luna","year":"2015","journal-title":"J Autoimmun"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00296-011-2003-y","article-title":"Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs","volume":"32","author":"F Fernanda","year":"2012","journal-title":"Rheumatol Int"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ki.2014.68","article-title":"High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies","volume":"86","author":"I Castillo","year":"2014","journal-title":"Kidney Int"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ndt\/17.2.239","article-title":"A comprehensive study of the association between hepatitis C virus and glomerulopathy","volume":"17","author":"A A Sabry","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2215\/CJN.04320416","article-title":"Viral-Associated GN: Hepatitis C and HIV","volume":"12","author":"W L Kupin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jare.2016.07.004","article-title":"Hepatitis C and kidney disease: A\u00a0narrative review","volume":"8","author":"R S Barsoum","year":"2017","journal-title":"J Adv Res"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jceh.2017.11.012","article-title":"Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of\u00a0the Road?","volume":"8","author":"C Bunchorntavakul","year":"2018","journal-title":"J Clin Exp Hepatol"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/annrheumdis-2012-201405","article-title":"Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey","volume":"72","author":"B Terrier","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1053\/j.ajkd.2015.12.007","article-title":"AJKD Atlas of Renal Pathology: Cryoglobulinemic Glomerulonephritis","volume":"67","author":"A B Fogo","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/0140-6736(93)93119-l","article-title":"Membranoproliferative glomerulonephritis and hepatitis C infection","volume":"341","author":"J R Harle","year":"1993","journal-title":"Lancet"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJM199302183280703","article-title":"Membranoproliferative glomerulonephritis associated with hepatitis C virus infection","volume":"328","author":"R J Johnson","year":"1993","journal-title":"N Engl J Med"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"L Gragnani","year":"2016","journal-title":"Hepatology"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study","volume":"75","author":"D Saadoun","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"M E Sise","year":"2016","journal-title":"Hepatology"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","article-title":"Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals","volume":"15","author":"M Bonacci","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13730-016-0244-z","article-title":"A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant","volume":"6","author":"F Obata","year":"2017","journal-title":"CEN Case Rep"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/hepr.12629","article-title":"Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report","volume":"46","author":"M Tsuge","year":"2016","journal-title":"Hepatol Res"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment","volume":"377","author":"E Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2468-1253(17)30116-4","article-title":"Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"A Bruchfeld","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.kint.2018.02.019","article-title":"Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4\/5 severe chronic kidney disease is safe and effective","volume":"94","author":"L Alric","year":"2018","journal-title":"Kidney Int"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00535-016-1174-4","article-title":"Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis","volume":"51","author":"H Toyoda","year":"2016","journal-title":"J Gastroenterol"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jvh.12553","article-title":"Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study","volume":"23","author":"Y Kawakami","year":"2016","journal-title":"J Viral Hepat"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"S De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ccr3.1371","article-title":"Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis","volume":"6","author":"A Koratala","year":"2018","journal-title":"Clin Case Rep"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"CD011403","DOI":"10.1002\/14651858.CD011403.pub2","article-title":"Treatment for hepatitis C virus-associated mixed cryoglobulinaemia","volume":"5","author":"N Montero","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/17474124.2018.1530984","article-title":"Renal complications of liver diseases","volume":"12","author":"J Noble","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"S 111","key":"ref157","first-page":"107","article-title":"Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study","volume":"36","author":"C Mazzaro","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/ajg.2017.49","article-title":"Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia","volume":"112","author":"J S Emery","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-018-0536-z","article-title":"Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis","volume":"19","author":"F Dammacco","year":"2019","journal-title":"Clin Exp Med"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.3748\/wjg.v20.i24.7544","article-title":"Hepatitis C virus associated glomerulopathies","volume":"20","author":"A Ozkok","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1056\/NEJM199302183280711","article-title":"Immune-complex glomerulonephritis \u2013 deposits plus interest","volume":"328","author":"G B Appel","year":"1993","journal-title":"N Engl J Med"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2249.2005.02778.x","article-title":"Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection","volume":"140","author":"D Sansonno","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10238-018-0514-5","article-title":"HCV-negative mixed cryoglobulinemia and kidney involvement: in-depth review on physiopathological and histological bases","volume":"18","author":"L Spatola","year":"2018","journal-title":"Clin Exp Med"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/acr.20381","article-title":"Hepatitis C virus-associated polyarteritis nodosa","volume":"63","author":"D Saadoun","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3899\/jrheum.080874","article-title":"Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry)","volume":"36","author":"M Ramos-Casals","year":"2009","journal-title":"J Rheumatol"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmed.2019.00020","article-title":"HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents","volume":"6","author":"A Angeletti","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/hep.29192","article-title":"Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study","volume":"66","author":"T S Lai","year":"2017","journal-title":"Hepatology"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.virol.2005.01.013","article-title":"HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis","volume":"334","author":"Sabry A, A EA, Sheashaa H et al","year":"2005","journal-title":"Virology"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41581-018-0081-8","article-title":"Hepatitis C virus and the kidney","volume":"15","author":"S Pol","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2215\/CJN.12621117","article-title":"Treatment Choices for Hepatitis C in Patients with Kidney Disease","volume":"13","author":"F Fabrizi","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2215\/CJN.03710708","article-title":"Hepatitis C infection and chronic renal diseases","volume":"4","author":"N Perico","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB et al. EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"73","author":"Association for the Study of the Liver European","year":"2020","journal-title":"J Hepatol"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1055\/a-0599-1320","article-title":"[Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection \u2013 AWMF-Register-No.: 021\/012]","volume":"56","author":"C Sarrazin","year":"2018","journal-title":"Z\u00a0Gastroenterol"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.kint.2018.06.011","article-title":"Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management","volume":"94","author":"M Jadoul","year":"2018","journal-title":"Kidney Int"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"361","author":"P Gines","year":"2009","journal-title":"N Engl J Med"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1053\/j.ajkd.2015.09.013","article-title":"Pathogenesis of Hepatorenal Syndrome: Implications for Therapy","volume":"67","author":"F Durand","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrgastro.2015.174","article-title":"The evolving concept of acute kidney injury in patients with cirrhosis","volume":"12","author":"F Wong","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/gut.2006.107789","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"F Salerno","year":"2007","journal-title":"Gut"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1055\/a-0928-2800","article-title":"[Updated S2k-Guideline \u201cComplications of liver cirrhosis\u201d. German Society of Gastroenterology (DGVS)]","volume":"57","author":"A L Gerbes","year":"2019","journal-title":"Z Gastroenterol"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"341","author":"P Sort","year":"1999","journal-title":"The New England journal of medicine"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.1840200619","article-title":"Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis","volume":"20","author":"A Follo","year":"1994","journal-title":"Hepatology"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/hep.21443","article-title":"Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features","volume":"45","author":"S Fasolato","year":"2007","journal-title":"Hepatology"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1053\/j.gastro.2005.09.024","article-title":"Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score","volume":"129","author":"C Terra","year":"2005","journal-title":"Gastroenterology"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s0016-5085(96)70068-9","article-title":"Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis","volume":"111","author":"A Gines","year":"1996","journal-title":"Gastroenterology"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/gut.2008.176495","article-title":"Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial","volume":"59","author":"P Angeli","year":"2010","journal-title":"Gut"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"E Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"ref188","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/gut.2008.154120","article-title":"The systemic inflammatory response syndrome is predictive of renal dysfunction in patients with non-paracetamol-induced acute liver failure","volume":"58","author":"J A Leithead","year":"2009","journal-title":"Gut"},{"key":"ref189","doi-asserted-by":"publisher","first-page":"4907024","DOI":"10.1155\/2018\/4907024","article-title":"Urinary Biochemistry in the Diagnosis of Acute Kidney Injury","volume":"2018","author":"C Lima","year":"2018","journal-title":"Dis Markers"},{"key":"ref190","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4254\/wjh.v5.i8.433","article-title":"Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?","volume":"5","author":"A Davenport","year":"2013","journal-title":"World J Hepatol"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s13054-016-1478-z","article-title":"Acute kidney injury 2016: diagnosis and diagnostic workup","volume":"20","author":"M Ostermann","year":"2016","journal-title":"Crit Care"},{"key":"ref192","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jhep.2016.05.025","article-title":"Kidney biomarkers in cirrhosis","volume":"65","author":"C Francoz","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"ref193","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/apt.13549","article-title":"Review article: sarcopenia in cirrhosis \u2013 aetiology, implications and potential therapeutic interventions","volume":"43","author":"M Sinclair","year":"2016","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"ref194","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jhep.2013.03.039","article-title":"Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites","volume":"59","author":"S Piano","year":"2013","journal-title":"Journal of hepatology"},{"key":"ref195","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1053\/j.gastro.2013.08.051","article-title":"New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection","volume":"145","author":"F Wong","year":"2013","journal-title":"Gastroenterology"},{"key":"ref196","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/hep.25735","article-title":"Association of AKI with mortality and complications in hospitalized patients with cirrhosis","volume":"57","author":"J M Belcher","year":"2013","journal-title":"Hepatology"},{"key":"ref197","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jhep.2013.04.036","article-title":"A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis","volume":"59","author":"C Fagundes","year":"2013","journal-title":"J Hepatol"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/gutjnl-2011-301255","article-title":"Acute kidney injury in decompensated cirrhosis","volume":"62","author":"C D Tsien","year":"2013","journal-title":"Gut"},{"key":"ref199","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1097\/MCG.0b013e31822e8e12","article-title":"Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites","volume":"46","author":"J R de Carvalho","year":"2012","journal-title":"Journal of clinical gastroenterology"},{"key":"ref200","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"62","author":"P Angeli","year":"2015","journal-title":"Journal of hepatology"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","article-title":"News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document","volume":"71","author":"P Angeli","year":"2019","journal-title":"J Hepatol"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/kisup.2012.7","article-title":"Summary of Recommendation Statements","volume":"2","author":"[Anonym]","year":"2012","journal-title":"Kidney international supplements"},{"key":"ref203","doi-asserted-by":"publisher","first-page":"m2687","DOI":"10.1136\/bmj.m2687","article-title":"Hepatorenal syndrome: pathophysiology, diagnosis, and management","volume":"370","author":"D A Simonetto","year":"2020","journal-title":"BMJ"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJM198809083191007","article-title":"Prerenal failure: a deleterious shift from renal compensation to decompensation","volume":"319","author":"K F Badr","year":"1988","journal-title":"N Engl J Med"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s10620-005-2671-0","article-title":"Loss of tubuloglomerular feedback in decompensated liver cirrhosis: physiopathological implications","volume":"50","author":"G Sansoe","year":"2005","journal-title":"Dig Dis Sci"},{"key":"ref206","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1053\/j.gastro.2007.10.055","article-title":"Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis","volume":"134","author":"V Stadlbauer","year":"2008","journal-title":"Gastroenterology"},{"key":"ref207","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa061","article-title":"Prerenal acute kidney injury-still a relevant term in modern clinical practice?","author":"A Bonavia","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"ref208","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(07)60196-2","article-title":"Wilson's disease","volume":"369","author":"A Ala","year":"2007","journal-title":"Lancet"},{"key":"ref209","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/B978-0-444-63625-6.00005-7","article-title":"Pathogenesis of Wilson disease","volume":"142","author":"I F Scheiber","year":"2017","journal-title":"Handb Clin Neurol"},{"key":"ref210","doi-asserted-by":"publisher","first-page":"527","DOI":"10.5692\/clinicalneurol.cn-000953","article-title":"Multiple pseudofractures due to Fanconi's syndrome associated with Wilson's disease","volume":"57","author":"M Tsuchiya","year":"2017","journal-title":"Rinsho Shinkeigaku"},{"key":"ref211","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s10072-015-2322-y","article-title":"Renal impairment in different phenotypes of Wilson disease","volume":"36","author":"H Wang","year":"2015","journal-title":"Neurol Sci"},{"key":"ref212","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/MEG.0b013e3283379768","article-title":"Membranous glomerulonephritis associated with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a very rare condition","volume":"22","author":"C Efe","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref213","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/hep.26599","article-title":"Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice","volume":"58","author":"P Fickert","year":"2013","journal-title":"Hepatology"},{"key":"ref214","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/ki.2013.78","article-title":"Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction","volume":"84","author":"C M van Slambrouck","year":"2013","journal-title":"Kidney Int"},{"key":"ref215","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/hep.22605","article-title":"Acute kidney injury in cirrhosis","volume":"48","author":"G Garcia-Tsao","year":"2008","journal-title":"Hepatology"},{"key":"ref216","doi-asserted-by":"publisher","first-page":"195","DOI":"10.14218\/JCTH.2015.00015","article-title":"Acute Kidney Injury in Patients with Cirrhosis","volume":"3","author":"K B Russ","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"ref217","doi-asserted-by":"publisher","first-page":"16550","DOI":"10.3748\/wjg.v20.i44.16550","article-title":"Retroperitoneal disorders associated with IgG4-related autoimmune pancreatitis","volume":"20","author":"N Hara","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref218","doi-asserted-by":"publisher","first-page":"e2550","DOI":"10.1097\/MD.0000000000002550","article-title":"IgG4-related Kidney Disease Mimicking Malignant Ureter Tumor: Case Report and Literature Review","volume":"95","author":"W H Lei","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref219","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.urology.2016.11.041","article-title":"Obstructive Nephropathy Without Hydronephrosis: Suspicion Is the Key","volume":"101","author":"D H Esprit","year":"2017","journal-title":"Urology"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1402-1502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:08:18Z","timestamp":1630404498000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1402-1502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":218,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2021,6,10]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1402-1502","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"type":"print","value":"0044-2771"},{"type":"electronic","value":"1439-7803"}],"subject":[],"published":{"date-parts":[[2021,3,16]]}}}